NCT04162600

Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

Since acceptable safety, tolerability, and immunogenicity was demonstrated at the highest dose tested (group 3, fully recruited), there was no scientific or ethical justification to recruit more participants into the mid-dose group (group 2).